Objective: The purpose of this study is to identify factors that affect survival of patients with differentiated thyroid carcinoma with bone metastases and to optimize surgical treatment modality for bone metastatic lesion by comparing duration of patient survival and local control. Methods: We examined 52 bone metastatic lesions from 40 patients with differentiated thyroid carcinoma who were treated surgically between 1994 and 2008 at Keio University Hospital. Median follow-up time was 46 months (range: 4 -233 months). Patients' disease-specific survival, local control duration and factors that potentially affected disease-specific survival after bone metastasis surgery were statistically analyzed. Results: The 2-, 5-and 10-year disease-specific survival rates were 77.2, 64.3 and 45.7%, respectively. Factors that were significantly associated with poor survival rates in multivariate analyses included age at bone metastasis surgery 65 years (P ¼ 0.0068), time from diagnosis of primary cancer to bone metastasis surgery 5 years (P ¼ 0.0018) and presence of visceral metastases (P ¼ 0.0092). The 2-, 5-and 10-year local control rates in our series were 91.4, 72.7 and 63.6%, respectively. The 5-year local control rates for radical and palliative surgery were 84.4 and 55.3%, respectively, and differed significantly (P ¼ 0.019). Conclusions: Because disease-specific survival of patients with differentiated thyroid carcinoma is fairly good, inadequate treatment of bone metastatic lesions can result in severe disabilities. Therefore, radical surgery for bone metastatic lesions should be considered, especially for those with favorable prognostic factors.
INTRODUCTION
Papillary carcinoma (PC) and follicular carcinomas (FC) of the thyroid gland, referred to together as differentiated thyroid carcinoma (DTC), are indolent malignancies with favorable prognoses (1) . PC and FC carry 10-year overall survival rates of 93 and 85%, respectively (1, 2) . Even patients diagnosed with metastatic DTC may experience long-term survival (3) . The skeletal system is the second most frequent metastatic destination after the lung, involving 2.3 -12.7% of the DTC cases (4 -11) . Bone metastatic lesions from DTC are predominantly osteolytic, and often result in skeletal pain, pathological fracture or spinal cord compression. These skeletal-related events (SRE) can severely compromise patients' quality of life (QOL) (12) . Patients with bone metastasis (BM) from DTC are commonly treated conservatively with radioactive iodine or external beam radiation therapy. However, given the relatively long survival and low radiosensitivity of DTC, these treatments are not always sufficient to avoid potential SRE. In those cases, surgeons and patients always face difficulties in choosing the appropriate treatment for skeletal lesions to balance with the physical burden of surgery. However, relatively few studies address this issue, and the optimal surgical modality for DTC patients with BM remains to be investigated (13) . To gain insight into this treatment strategy, we reviewed patients who were surgically treated for BM from DTC and analyzed the outcomes and factors involved in their survival and mortality.
PATIENTS AND METHODS

PATIENTS
We reviewed 40 patients with BM from DTC who were surgically treated at Keio University Hospital between 1994 and 2008, with emphasis on clinical factors that potentially affect survival. Although decisions regarding surgical treatment were made on a case-by-case basis, surgery was performed in cases that fulfilled the following criteria: expected prognosis of at least 3 months and expected improvements in performance status (ECOG, ,4), QOL and pain relief. Indications for surgery ranged widely, and included treatment for severe pain, risk or presence of pathological fracture, risk or presence of spinal cord compression and goal of disease-free status. Sternal lesions were often surgically removed to prevent the risk of cardiac failure. BM surgery was classified as either palliative surgery or radical surgery for the convenience of statistical analysis. The former included intra-tumoral curettage, fixation of the long bone without tumor resection, and decompression and posterior fusion of the spine without complete tumor resection (R2 resection). The latter included marginal or wide resection of the tumor (R0 and R1 resection) and total en bloc spondylectomy of the spine.
The study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the institutional review board of Keio University Hospital.
STATISTICAL ANALYSIS
Disease-specific survival and local control duration were estimated using the Kaplan -Meier method and the impact of each prognostic factor was assessed using the log-rank test. Disease-specific survival duration was defined as the time from the first surgery for BM to the date of the last visit to the clinic or death. Local control duration was defined as the time from the surgery for BM to the date of the last visit to the clinic, death or the date that the lesion in the surgical site became symptomatic and required further treatments. Complications directly related to the surgery, such as infection and hardware failure, were evaluated separately from the local control analysis. Clinical variables included sex, age at initial diagnosis of primary DTC (,55 or 55 years), age at surgery for BM (,65 or 65 years), histological subtype of DTC (FC or PC), time from diagnosis of the primary cancer to BM surgery (,5 or 5 years), number of detectable bone lesions and the presence of visceral metastatic lesions (such as lung, brain or gastrointestinal tract) present at the time of BM surgery. Variables with P , 0.05 in univariate analysis were considered significantly associated with the survival and were further analyzed by multivariate analysis using Cox's proportional hazard method to identify independent prognostic factors. All statistical analyses were performed using JMP10 (SAS Institute Inc., Cary, NC, USA).
RESULTS
PATIENT CHARACTERISTICS AND CLINICOPATHOLOGIC FEATURES
Patient demographics and survival analysis are summarized in Table 1 . Median follow-up time was 46 months (range: 4 -233 months) after BM surgery; four cases were lost to follow-up. Our series had 16 male and 24 female patients; 12 patients had PC and 28 had FC. Mean age at initial diagnosis of the primary cancer was 48.8 years (range: 18 -71 years); mean age at BM surgery was 59.0 years (range: 23 -81 years). Most patients developed BM after their fifth decade of life (Fig. 1a) . In one quarter of the patients referred to our service, BM was found prior to the identification of the primary DTC (Fig. 1b) . In half of the patients, BM was found .5 years after their initial diagnosis of DTC (Fig. 1b) . Twenty patients had metastasis solely in the bone and the other 20 had metastases in visceral organs, including the lung, brain and gastrointestinal tract. Nineteen patients had solitary lesions and the other 21 had multiple BM lesions.
Fifty-two lesions in 40 patients were surgically treated; their anatomical distribution and surgical treatment are listed in Table 2 . The most common site was the spine (18 cases) followed by the pelvis (15 cases); these two sites accounted for two-thirds of all treated lesions. Most BM lesions in the long bones were radically treated, whereas 14 cases out of 33 spinal and pelvic lesions (42.4%) were treated in a palliative manner (as described in the Patients and Methods section). Neither pre-nor post-operative radiotherapy was given to the patients in the study in an adjuvant setting because of the low radiosensitivity of BM lesions from DTC.
SURVIVAL OUTCOMES AND PROGNOSTIC FACTORS
Disease-specific survival curves from the time of BM surgery and from initial diagnosis of primary DTC are shown in Fig. 2 . Survival analysis showed that the 2-, 5-and 10-year disease-specific survival rates from the time of BM surgery in this cohort were 77.2, 64.3 and 45.7%, respectively (Fig. 2a) , and the 5-, 10-and 20-year disease-specific survival rates from initial diagnosis of primary DTC were 100.0, 91.4 and 37.4% (Fig. 2b) , respectively. Sex, age at initial diagnosis of primary carcinoma, histology of the primary cancer and BM location had no prognostic significance ( (Table 1) . Furthermore, we found that disease-specific survival was inversely correlated with the number of the negative prognostic factors that patients exhibited at BM surgery ( Fig. 4 and Table 3 ). Patients who exhibited all three negative prognostic factors (i.e. age at BM surgery 65 years, time from diagnosis of primary cancer to BM surgery 5 years, and presence of visceral metastasis) showed extremely poor survival (median survival time: 16.7 months), whereas those with none or one of the negative prognostic factors showed excellent survival. 
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Optimal surgery for bone metastases in DTC
To address the optimal surgical treatment for BM from DTC, we analyzed the difference in long-term local control rates between palliative surgeries and radical surgeries, as defined in the Patients and Methods. We defined 'local control failure' as the situation where progression of the recurrent or residual tumors at the surgical site become symptomatic and require further treatment. We excluded complications that were directly related to the BM surgery, such as infection and hardware failure, from the local control failure in this analysis. There were nine BM lesions (9/52, 17.3%) that developed local control failure (Table 2) , of which seven were attributed to progression of residual tumors among those who underwent palliative surgery (7/17, 41.2%), whereas only two recurrent lesions were from those who underwent radical surgery (2/35, 5.7%). Eight were either progression of the residual tumors or recurrent tumors from the spine or pelvis; the ninth patient 
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developed a recurrent tumor from the base of the second rib and underwent subsequent total en bloc spondylectomy. Local control duration curves from the time of BM surgery are shown in Fig. 5 . The 2-, 5-and 10-year local control rates in our series were 91.4, 72.7 and 63.6% (Fig. 5a ). The 5-year local control rates of the radical and palliative surgery were 84.4 and 55.3%, respectively, and the difference between the two groups was statistically significant (P ¼ 0.019) (Fig. 5b) .
SURGICAL COMPLICATIONS
Complications after BM surgeries are summarized in Table 4 . Of seven patients who developed complications, five were in the radical surgery group and two in the palliative surgery group. Statistical differences were insignificant between the two groups.
DISCUSSION
This study analyzes long-term follow-up of 40 DTC patients with BM who were surgically treated in our hospital. DTC is associated with a good prognosis even in the presence of metastatic diseases. A primary objective of the present study was to identify factors that most significantly affect survival of DTC patients with BM. We found that age at BM surgery 
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Optimal surgery for bone metastases in DTC 65 years, time from diagnosis of primary cancer to BM surgery 5 years and presence of visceral metastases were statistically significant independent prognostic factors in multivariate analysis. Disease-specific survival rates after BM surgery in the current study (5 year: 64.3%, 10 year: 45.7%) were comparable to those in previous studies that analyzed clinical outcomes of BM cases from DTC irrespective of surgical treatment (5 year: 41 -58.8%, 10 year: 15 -38.5%) (11, 14) . A slightly higher survival rate in our cases may be attributed to a selection bias, as we solely included patients who underwent surgical treatment for their BM lesions. Nevertheless, as previously reported, our study confirmed that DTC patients with BM have relatively fair prognoses compared with other types of malignancies (15) .
Of the histological subtypes, PC is far more common than FC as a primary DTC. A previous study showed that PC and FC cases constitute 78.4 and 17.2% of all the DTC cases, respectively (16) . However, FC is more likely to metastasize to distant organs such as lung and bone (17) , whereas PC tends to metastasize to regional lymph nodes (18) . Therefore, BM are more often found in FC cases (1, 2, 7, 19, 20) . This trend was also observed in the present study (FC cases: 28; PC cases: 12).
In general, the patient's age is one of the strongest prognostic factors in DTC, as older patients have poorer cancerspecific survival than younger patients (21,22) , irrespective of the presence or absence of metastatic lesions (3,19,22 -24) . In our study, patient demographics were comparable with past reports; age at BM surgery 65 years was consistently found to be a strong prognostic factor. This result was confirmed using Cox's proportional hazard method with age at BM surgery as a continuous variable (P , 0.0001, data not shown). Although the age of 65 years was an arbitrary cutoff value that showed age at BM surgery to be most significant in univariate analysis, it can be an indicative figure in the clinical setting. On the other hand, age at primary DTC showed no statistical significance on prognosis; this may be attributable to a selection bias in the current study, which included only BM cases.
Intriguingly, the results suggest a negative correlation between the disease-specific survival rate and the time from diagnosis of the primary lesion to the development of BM. A previous study also showed similar results (11) . These observations may imply that development of BM at an early clinical stage does not necessarily reflect the aggressiveness of the tumor cells. Alternatively, better survival in those who underwent BM surgery ,5 years after diagnosis of the primary cancer may reflect lead-time bias, whereby the patients diagnosed with BM at an early clinical stage appear to survive longer than those who were diagnosed with BM at a later stage. Time from diagnosis of the primary cancer to BM surgery was not a significant prognostic factor when we Jpn J Clin Oncol 2014;44(10) 923
analyzed survival from diagnosis of the primary cancer (data not shown). In this context, the survival curve seen in Fig. 2b should be a good predictor of BM patients' survival. Further study is required to elucidate this issue. Nevertheless, approximately one-third of the patients who underwent BM surgery for .5 years after diagnosis of the primary tumor survived for .5 years afterwards (Fig. 3b) .
The other important objective of the study was to address the optimal surgical treatment ( palliative or radical surgery) for BM from DTC. To gain an insight into it, we analyzed the local control rate in our series and investigated how it related to the patients' survival rate. Although the overall diseasespecific survival rate was lower than the local control rate (Figs 2a and 5a) , the local control rate in patients who underwent palliative surgery was inferior to the disease-specific survival rate (Figs 2a and 5b) and of the 17 cases who underwent palliative surgery, seven (41.2%) developed local control failure ( Table 2) . The results could be biased by the relatively small sample size and the retrospective nature of the present study; however, our observations suggest that radical surgery should be considered when the patients have one or none of the three negative prognostic factors shown in Fig. 4 (age at BM surgery 65 years, time from diagnosis of primary cancer to BM surgery 5 years, and presence of visceral metastasis). Palliative surgery may be used for patients who are positive for all three negative prognostic factors, as these patients are likely to have less favorable outcomes. Most importantly, the present study showed that approximately two-thirds of patients with BM that required surgical treatment had spinal or pelvic lesions; 42.4% of these lesions (14/33) were treated palliatively and 82.4% of the palliatively treated lesions (14/17) were in the spine or pelvis (Table 2) . Radical resection of the tumors in the spine and pelvis is technically challenging because of the anatomical complexities and it is often accompanied by significant functional loss and complications, which were not analyzed in this study. Therefore, efforts should be undertaken for improved surgical techniques, and to establish novel multi-modal treatments for DTC. Furthermore, long-term follow-up by orthopedic oncologists of patients who undergo BM surgery is important, to check long-term local control failure at the surgery sites, and for late complications of surgery, such as infection and implant failures and development of new BM lesions.
This study had several limitations. Because most patients were referred to our service from other hospitals or clinics, complete clinical data at the time of the initial treatment for the primary DTC were not always available. We therefore could not statistically analyze the effects of primary tumor size, TNM staging, treatment procedures (e.g. total or partial thyroidectomy, with or without lymph node dissection) or thyroglobulin values on the clinical outcome. In a similar vein, although patients who underwent total thyroidectomy and later developed metastatic disease that showed positive uptake in the radioiodine scintigraphy were routinely treated with radioactive iodine ( 131 I), we could not evaluate the effects of this treatment as a variable in the statistical analysis because of incomplete clinical data. Four patients were lost to follow-up once they felt free from the risk of SRE. In addition, we could not evaluate the effects of anti-osteoclastic agents in the present study, such as zoledronic acid and Denosumab, which are nowadays widely used to treat patients with BM.
CONCLUSIONS
Our results suggest that age at BM surgery 65 years, time from initial diagnosis of the primary tumor to BM surgery 5 years, and presence of visceral metastases are the most reliable independent prognostic factors for DTC patients with BM. As disease-specific survival of patients with DTC is fairly good, surgical treatment should be attempted by procedures that can maintain physical function and mobility as long as possible, such as tumor resection and functional reconstruction, especially for those who exhibit none or one of the abovementioned negative prognostic factors. Palliative surgery with less invasive procedures, such as internal fixation without tumor resection, should be applied with caution, as these treatments may not be sufficient to prevent potential SRE over the long term.
